On the public citation graph

Additional baricitinib loading dose improves clinical outcome in COVID-19

https://doi.org/10.1515/med-2021-0010
0 signed · 42 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1001/jama.2020.4683openalex-snapshot
Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy
inferredcites →https://doi.org/10.1002/cpt.936openalex-snapshot
Pharmacokinetics, Pharmacodynamics, and Proposed Dosing of the Oral JAK1 and JAK2 Inhibitor Baricitinib in Pediatric and Young Adult CANDLE and SAVI Patients
inferredcites →https://doi.org/10.1002/jmv.25801openalex-snapshot
Tocilizumab treatment in COVID‐19: A single center experience
inferredcites →https://doi.org/10.1007/s00134-020-05991-xopenalex-snapshot
Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China
inferredcites →https://doi.org/10.1007/s15010-020-01476-7openalex-snapshot
Baricitinib as rescue therapy in a patient with COVID-19 with no complete response to sarilumab
inferredcites →https://doi.org/10.1007/s40290-020-00342-zopenalex-snapshot
IL-6 Inhibitors in the Treatment of Serious COVID-19: A Promising Therapy?
inferredcites →https://doi.org/10.1016/j.jaut.2020.102468openalex-snapshot
The anti-viral facet of anti-rheumatic drugs: Lessons from COVID-19
inferredcites →https://doi.org/10.1016/j.jinf.2020.04.017openalex-snapshot
Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact
inferredcites →https://doi.org/10.1016/s0140-6736(20)30183-5openalex-snapshot
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
inferredcites →https://doi.org/10.1016/s0140-6736(20)30211-7openalex-snapshot
Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study
inferredcites →https://doi.org/10.1016/s0140-6736(20)30304-4openalex-snapshot
Baricitinib as potential treatment for 2019-nCoV acute respiratory disease
inferredcites →https://doi.org/10.1038/nbt1358openalex-snapshot
A quantitative analysis of kinase inhibitor selectivity
inferredcites →https://doi.org/10.1038/ni.3153openalex-snapshot
IL-6 as a keystone cytokine in health and disease
inferredcites →https://doi.org/10.1086/423808openalex-snapshot
Temporal Relationship of Viral Load, Ribavirin, Interleukin (IL)–6, IL‐8, and Clinical Progression in Patients with Severe Acute Respiratory Syndrome
inferredcites →https://doi.org/10.1161/circulationaha.120.047915openalex-snapshot
Differentiating COVID-19 Pneumonia From Acute Respiratory Distress Syndrome and High Altitude Pulmonary Edema
inferredcites →https://doi.org/10.1172/jci141772openalex-snapshot
Baricitinib restrains the immune dysregulation in patients with severe COVID-19
inferredcites →https://doi.org/10.1186/s13075-019-1964-1openalex-snapshot
Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations
inferredcites →https://doi.org/10.3389/fimmu.2018.01510openalex-snapshot
Janus Kinase Inhibitor Baricitinib Modulates Human Innate and Adaptive Immune System

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.2139/ssrn.3929406openalex-extracted
Clinical Efficacy and Adverse Events of Baricitinib Treatment for Coronavirus Disease-2019 (COVID-19): A Systematic Review and Meta-Analysis
inferred← citeshttps://doi.org/10.1002/14651858.cd015209openalex-snapshot
Janus kinase inhibitors for the treatment of COVID-19
inferred← citeshttps://doi.org/10.1002/eji.202048922openalex-snapshot
JAK inhibitors: Ten years after
inferred← citeshttps://doi.org/10.1002/jmv.27482openalex-snapshot
Clinical efficacy and adverse events of baricitinib treatment for coronavirus disease‐2019 (COVID‐19): A systematic review and meta‐analysis
inferred← citeshttps://doi.org/10.1002/mco2.154openalex-snapshot
Inflammatory pathways in COVID‐19: Mechanism and therapeutic interventions
inferred← citeshttps://doi.org/10.1002/med.21951openalex-snapshot
Use of baricitinib in treatment of COVID‐19: a systematic review
inferred← citeshttps://doi.org/10.1016/b978-0-323-91172-6.00018-2openalex-snapshot
Currently available drugs for the treatment of Coronavirus-2
inferred← citeshttps://doi.org/10.1016/j.bcp.2022.115162openalex-snapshot
JAK inhibition as a new treatment strategy for patients with COVID-19
inferred← citeshttps://doi.org/10.1016/j.ejim.2022.05.014openalex-snapshot
Treatment strategies of COVID-19: A rheumatology perspective
inferred← citeshttps://doi.org/10.1016/j.ijbiomac.2023.125096openalex-snapshot
Investigation on the binding behavior of human α1-acid glycoprotein with Janus Kinase inhibitor baricitinib: Multi-spectroscopic and molecular simulation methodologies
inferred← citeshttps://doi.org/10.1016/j.intimp.2021.108027openalex-snapshot
Clinical efficacy and safety of Janus kinase inhibitors for COVID-19: A systematic review and meta-analysis of randomized controlled trials
inferred← citeshttps://doi.org/10.1016/j.jinf.2021.05.011openalex-snapshot
Secukinumab in severe COVID-19 pneumonia: Does it have a clinical impact?
inferred← citeshttps://doi.org/10.1016/j.rmed.2022.106986openalex-snapshot
Does baricitinib reduce mortality and disease progression in SARS-CoV-2 virus infected patients? A systematic review and meta analysis
inferred← citeshttps://doi.org/10.1038/s41392-021-00679-0openalex-snapshot
The signal pathways and treatment of cytokine storm in COVID-19
inferred← citeshttps://doi.org/10.1080/17476348.2022.2114899openalex-snapshot
Therapeutic and anti-inflammatory effects of baricitinib on mortality, ICU transfer, clinical improvement, and CRS-related laboratory parameters of hospitalized patients with moderate to severe COVID-19 pneumonia: a systematic review and meta-analysis
inferred← citeshttps://doi.org/10.1097/sla.0000000000005571openalex-snapshot
Inhibition of the JAK/STAT Pathway With Baricitinib Reduces the Multiple Organ Dysfunction Caused by Hemorrhagic Shock in Rats
inferred← citeshttps://doi.org/10.1186/s12879-021-06119-2openalex-snapshot
Impact of high dose of baricitinib in severe COVID-19 pneumonia: a prospective cohort study in Bangladesh
inferred← citeshttps://doi.org/10.14710/dmj.v11i5.35628openalex-snapshot
Baricitinib as Treatment Option for Corona Virus Disease-19: a Literature Review
inferred← citeshttps://doi.org/10.18103/mra.v10i9.3076openalex-snapshot
Survival Benefit of High Dose Versus Usual Dose of Baricitinib in Hospitalized Patients with COVID-19: A Systematic Review
inferred← citeshttps://doi.org/10.24321/0019.5138.202232openalex-snapshot
Pathogenesis of the SARS Coronavirus-2 and Potential Therapeutic Strategies
inferred← citeshttps://doi.org/10.3390/ph14080738openalex-snapshot
Janus Kinase Inhibitors and Coronavirus Disease (COVID)-19: Rationale, Clinical Evidence and Safety Issues
inferred← citeshttps://doi.org/10.3390/pharmaceutics14051001openalex-snapshot
A Comprehensive Overview of Globally Approved JAK Inhibitors
inferred← citeshttps://doi.org/10.5339/qmj.2021.66openalex-snapshot
One-year Review of COVID-19 in the Arab World
inferred← citeshttps://doi.org/10.5772/intechopen.107269openalex-snapshot
Baricitinib in the Treatment of COVID-19
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.